Cleveland Clinic, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195 USA.
J Invasive Cardiol. 2020 May;32(5):161-168. doi: 10.25270/jic/19.00495.
To investigate the impact of novel, polymer-jacketed, tapered-tip, low-force guidewires with composite-core, dual-coil design (Fielder XT-R and Fielder XT-A; Asahi Intecc) on antegrade wire escalation (AWE) crossing of coronary chronic total occlusion (CTO) lesions.
From March of 2017 to December 2018, a total of 164 consecutive CTO lesions at a single institution were treated with a primary AWE strategy using either Fielder XT-R or XT-A (XTRA) as the starting wire regardless of lesion characteristics. Success rates, wiring times, and complications were analyzed.
The mean Japanese (J)-CTO score was 3.71 ± 1.27, mean PROGRESS-CTO score was 2.46 ± 1.15, and mean PROGRESS-CTO Complications score was 3.9 ± 2.0. Mean CTO length was 25.0 ± 0.5 mm, 48 lesions (29.3%) were previously bypassed, 77 lesions (47.0%) had moderate to severe calcification, and 62 lesions (37.8%) had moderate to severe tortuosity. Antegrade success rates using XTRA wires were 79%, 60%, and 17% of lesions with J-CTO scores of 0-1, 2-3, and 4-5, respectively. In successful antegrade XTRA cases, median wiring times were 6.5 min (interquartile range [IQR], 5.0-11.0 min), 9.0 min (IQR, 4.2-14.0 min), and 12.0 min (IQR, 9.0-15.0 min) for J-CTO scores of 0-1, 2-3, and 4-5, respectively, and differed non-significantly according to J-CTO score (P=.20). Complication rates were low (In-hospital major adverse cardiac event rate, 1.3%) with no wire perforations caused by XTRA wires.
Use of Fielder XTRA wires as part of an AWE strategy in CTO percutaneous coronary interventions may facilitate more efficient antegrade lesion crossing and overall procedural success in lesions that have been traditionally challenging to treat using an antegrade-first approach.
研究新型聚合物护套、锥形尖端、低力导丝与复合芯、双线圈设计(Fielder XT-R 和 Fielder XT-A;Asahi Intecc)对冠状动脉慢性完全闭塞(CTO)病变正向导丝升级(AWE)穿越的影响。
2017 年 3 月至 2018 年 12 月,在一家医疗机构中,共对 164 例连续的 CTO 病变采用 AWE 策略进行治疗,无论病变特征如何,均将 Fielder XT-R 或 XT-A(XTRA)作为起始导丝。分析成功率、布线时间和并发症。
平均日本(J)-CTO 评分 3.71 ± 1.27,平均 PROGRESS-CTO 评分 2.46 ± 1.15,平均 PROGRESS-CTO 并发症评分 3.9 ± 2.0。平均 CTO 长度为 25.0 ± 0.5mm,48 例(29.3%)为既往旁路,77 例(47.0%)有中重度钙化,62 例(37.8%)有中重度迂曲。使用 XTRA 导丝的正向成功率分别为 J-CTO 评分 0-1、2-3 和 4-5 的病变的 79%、60%和 17%。在成功的正向 XTRA 病例中,J-CTO 评分 0-1、2-3 和 4-5 的中位数布线时间分别为 6.5min(IQR,5.0-11.0min)、9.0min(IQR,4.2-14.0min)和 12.0min(IQR,9.0-15.0min),根据 J-CTO 评分差异无统计学意义(P=.20)。并发症发生率较低(院内主要不良心脏事件发生率为 1.3%),无 XTRA 导丝引起的穿孔。
在 CTO 经皮冠状动脉介入治疗中,将 Fielder XTRA 导丝作为 AWE 策略的一部分使用,可能有助于更有效地正向病变穿越,并提高传统上难以采用正向优先方法治疗的病变的整体手术成功率。